Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 02:12:01 PM Mon, 8 Jun 2020   Contact Information Michael Curran Associated Profiles  Associate Professor, Immunology, UT MD Anderson Cancer Center     MCurran@mdanderson.org    Web Link    Lab Webpage    T-Lymphocytes, Neoplasms, Immunotherapy, Feline Immunodeficiency Virus, Immunity, Cancer Vaccines, Tumor Microenvironment, Regulatory T-Lymphocytes    Associated Profiles Professional Preparation Research and Expertise Affiliations Appointments  Professional Preparation  Degree Major Institution Year  PhD Immunology Stanford University 2001  BA Biology, Foreign Affairs University of Virginia 1995  Research and Expertise Research Interests   While pursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential manuscripts describing how T cell co-stimulatory pathways could be modulated in tandem to mediate immunologic rejection of melanomas in mice. Dr. Curran described how combination blockade of the T cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of a majority of murine melanomas. This work supported the launch of a Phase I clinical trial in which greater than 50% of metastatic melanoma patients experienced objective clinical responses - a result so unprecedented that this became the first FDA-approved immunotherapy combination. In addition, his subsequent immunologic studies of 4-1BB agonist antibodies earned him the Society for the Immunotherapy of Cancer's prestigious Presidential Award. At the MD Anderson Cancer Center, Dr. Curran is an Associate Professor of Immunology as well as co-Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) program that coordinates development and production of clinical immunotherapeutic antibodies. The Curran Lab seeks to discover the underlying mechanisms of immune resistance in the "coldest" tumors, pancreatic and prostate adenocarcinoma and glioblastoma, so that rational therapeutic interventions can be developed to restore T cell infiltration and sensitivity to T cell checkpoint blockade (for which TIL are the substrate).  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia Gulf Coast Consortia Immunology Cluster  Appointments Title Department / School Institution Associate Professor Immunology UT MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.